Potential of cannabinoids in the treatment of hepatocellular carcinoma
Palavras-chave:
Cannabinoids, Hepatocellular carcinoma, Hepatic NeoplasiaResumo
In 1964 the Δ9-Tetrahydrocannabinol was isolated and identified for the first time by Gaoni and Mechoulam. After 26 years, in 1990, the CB1 and CB2 receptors responsible for the action of these cannabinoids were identified, as well as the endogenous substances, derived from arachidonic acid, related to their activation (anandamide and 2-AG). The CB1 receptor is more present in presynaptic neurons, and is responsible for the great majority of the neurobehavioral effects of cannabinoids through a mechanism of inhibition of neurotransmitter release (regulating the action of ion channels). The CB2 receptor is mainly found on the immune system cells, where it acts modulating the release of cytokines.
DOI: 10.56238/homeinternationalanais-072
Downloads
Publicado
2023-02-01
Como Citar
Farias, A., Maas, R., Souza, P., Boguchewski, M., & Marques, C. (2023). Potential of cannabinoids in the treatment of hepatocellular carcinoma. Caderno De ANAIS HOME. Recuperado de https://homepublishing.com.br/index.php/cadernodeanais/article/view/74
Edição
Seção
Articles